Alexis Pharmacy Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 15-11-2024
- Paid Up Capital ₹ 1.00 M
as on 15-11-2024
- Company Age 8 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 9.33%
(FY 2023)
- Profit 27.64%
(FY 2023)
- Ebitda 27.93%
(FY 2023)
- Net Worth 35.46%
(FY 2023)
- Total Assets 14.14%
(FY 2023)
About Alexis Pharmacy
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Mohammad Shams, Zanubia Shams, and Shabbar Daud serve as directors at the Company.
- CIN/LLPIN
U74999MH2016PTC282079
- Company No.
282079
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Jun 2016
- Date of AGM
05 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Nagpur, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Alexis Pharmacy Private Limited offer?
Alexis Pharmacy Private Limited offers a wide range of products and services, including Medical Surgery & Treatment Centres, Medical Treatment Services, Medical Consultants & Clinics, Dermatology Treatment Services.
Who are the key members and board of directors at Alexis Pharmacy?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mohammad Shams  | Director | 06-Jun-2016 | Current |
| Zanubia Shams | Director | 06-Jun-2016 | Current |
| Shabbar Daud | Director | 05-Mar-2024 | Current |
Financial Performance and Corporate Structure Insights of Alexis Pharmacy.
Alexis Pharmacy Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 9.33% increase. The company also saw a substantial improvement in profitability, with a 27.64% increase in profit. The company's net worth Soared by an impressive increase of 35.46%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Alexis Pharmacy?
In 2023, Alexis Pharmacy had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Alexis Pharmacy?
Alexis Pharmacy has a workforce of 20 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Alexis Pharmacy, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Alexis Pharmacy's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
